Microalbuminuria in Obese Young and Middle Aged Population: A Potential Marker of Cardiovascular Risk

Purvi Purohit1, Kunal Garg2, Vikram Singh3

  • 1Department of Biochemistry, AIIMS Jodhpur, Jodhpur, India.

Insights

Microalbuminuria (MAU) is common in healthy obese Indian adults, indicating increased cardiovascular risk and prediabetes. Routine screening for MAU in this population is recommended for better health outcomes.

Area of Science:

  • Endocrinology
  • Cardiology
  • Nephrology

Background:

  • Microalbuminuria (MAU) is a known cardiovascular risk indicator.
  • Limited data exists on MAU prevalence in healthy obese Indian adults.
  • Debate continues regarding targeted screening for MAU and prediabetes in obese populations.

Purpose of the Study:

  • To determine the prevalence of MAU and prediabetes in healthy obese young and middle-aged Indian adults.
  • To investigate the association between MAU, prediabetes, and cardiovascular risk using the Framingham Risk Score (FRS).

Main Methods:

  • A study involving 50 healthy obese adults (aged 20-50 years) was conducted over two months.
  • Screening included fasting blood sugar, lipid profile, and MAU.
  • Data was analyzed using Pearson's Correlation and FRS for 10-year CVD risk assessment.

Main Results:

  • 28% of participants had MAU, with 32.14% of those having prediabetes and 33.33% having diabetes.
  • Younger obese adults (Group I) showed a 50% MAU prevalence, while middle-aged adults (Group II) had 25% MAU and 63.63% prediabetes.
  • MAU correlated with age, BMI, blood pressure, and waist-to-hip ratio (p < 0.05).
  • Individuals with MAU exhibited a higher 10-year CVD risk based on FRS.

Conclusions:

  • Healthy obese Indian adults, both young and middle-aged, are at risk for prediabetes and MAU.
  • Elevated MAU is associated with increased cardiovascular risk in this demographic.
  • Routine screening for MAU and prediabetes in obese Indian adults is crucial for improved clinical outcomes.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
269
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
332
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
357
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
715